In late December 2023, a 41‑year‑old mother of two from Colorado experienced a crackling sensation in her lungs that progressed to an intermittent cough. On December 27, she coughed up blood, prompting an urgent medical evaluation.
Rapid Diagnosis and Initial Treatment
After an initial exam, her physician ordered a chest X‑ray, which revealed an abnormality that required further testing. The same day she underwent a chest CT scan at an urgent‑care facility. The urgent‑care doctor reported a positive COVID‑19 test, pneumonia, and an additional unexplained finding in the chest. A subsequent lymph‑node biopsy confirmed small‑cell lung cancer (SCLC). While one specialist suggested the disease often responds well to therapy, another oncologist explained that the average survival for SCLC is one to two years.
The patient, who had never smoked and previously had only a single melanoma removed in her early 20s, was shocked by the diagnosis. She and her husband quickly organized a plan: the husband handled research and alerts on emerging treatments while she focused on recovery.
Initial therapy consisted of six rounds of chemotherapy combined with six weeks of chest radiation. When imaging later identified 30 metastatic lesions in the brain, she underwent a ten‑day course of whole‑brain radiation, which caused significant scalp and forehead sensitivity that persists.
Recurrence and Access to a New Immunotherapy
Follow‑up scans after the first round of chemo‑radiation showed tumor shrinkage, offering a brief period of optimism through the summer of 2024. However, a subsequent chest CT revealed new cancer growths, confirming disease progression.
Her oncologist then enrolled her in a trial of Imdelltra, a newly approved immunotherapy offered at the University of Colorado Anschutz Medical Campus. The drug is designed to help the immune system locate and destroy small‑cell lung cancer cells. She received the first intravenous infusion on October 8, 2024, which lasted about an hour followed by a two‑hour observation period. The treatment schedule calls for infusions every two weeks.
Early scans after starting Imdelltra indicated further tumor reduction. Multiple consecutive scans later showed no detectable disease, prompting her physician to describe her status as “consistently No Evidence of Disease,” while cautioning against labeling it full remission.
Personal Impact and Outlook
Approaching her 45th birthday, the patient reflects on how the diagnosis reshaped her priorities. She emphasizes the importance of sleep, nutrition, exercise, and a positive mindset while acknowledging the uncertainty of how long Imdelltra will remain effective.
Beyond her own health journey, she highlights broader lung‑cancer statistics: lung cancer is the second most common cancer among both men and women, with roughly 229,000 new cases diagnosed annually in the United States, and it remains the leading cause of cancer death. Common symptoms include a persistent cough, coughing up blood, chest pain, hoarseness, shortness of breath, and wheezing. While smoking is the primary risk factor, about 20 % of patients have never smoked, and other contributors can include genetics, air pollution, secondhand smoke, asbestos, and various environmental toxins.
Her story underscores that small‑cell lung cancer can affect individuals without traditional risk factors and that emerging therapies such as immunotherapy may alter previously grim prognoses.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.




